Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04088734 · ClinicalTrials.gov registry record · Phase 1
Gene Transfer Study of ABO-102 in Patients With Middle and Advanced Phases of MPS IIIA Disease
A Phase 1 study, sponsored by Ultragenyx Pharmaceutical.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT04088734 is a Phase 1 study that was terminated before completion, run by Ultragenyx Pharmaceutical. The registered enrollment target is 5 participants.
The verdict
NCT04088734, a Phase 1 study, was terminated before completion, sponsored by Ultragenyx Pharmaceutical.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
Open-label, clinical trial of scAAV9.U1a.hSGSH injected intravenously through a peripheral limb vein
Interventions
- DRUG ABO-102
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2019-09-18 |
| Est. Completion | 2022-03-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04088734
The ClinicalTrials.gov registry entry for NCT04088734 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ultragenyx Pharmaceutical, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ABO-102 is the first listed.
NCT04088734 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04088734 about?
NCT04088734 is a clinical study titled "Gene Transfer Study of ABO-102 in Patients With Middle and Advanced Phases of MPS IIIA Disease". Open-label, clinical trial of scAAV9.U1a.hSGSH injected intravenously through a peripheral limb vein
What is the current status of trial NCT04088734?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2019-09-18. Estimated completion is 2022-03-10.
What interventions are being tested in trial NCT04088734?
The interventions under investigation include: ABO-102 (DRUG).
Who is sponsoring clinical trial NCT04088734?
This trial is sponsored by Ultragenyx Pharmaceutical, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.